Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | OGA | O60502 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | DNM1L | O00429 | 10/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7185717 | 0.96 | HRH3 (0.47) | HRH3OGASMN1; SMN2ARTP53 | |
| SCHEMBL10465680 | 0.95 | SMN1; SMN2 (0.49) | HRH3OGASMN1; SMN2ARTP53 | |
| SCHEMBL16603143 | 0.86 | MAPT (0.51) | OGASMN1; SMN2ARRAB9AMAPT | |
| SCHEMBL10464688 | 0.86 | AR (0.50) | HRH3OGASMN1; SMN2ARTP53 | |
| SCHEMBL7187027 | 0.84 | MAPT (0.56) | OGASMN1; SMN2ARRAB9AMAPT | |
| SCHEMBL10465564 | 0.84 | OGA (0.50) | HRH3OGASMN1; SMN2RAB9AMAPT | |
| SCHEMBL15356491 | 0.82 | HRH3 (0.46) | HRH3OGAARDNM1LMAPT | |
| SCHEMBL5724279 | 0.79 | HRH3 (0.43) | HRH3OGADNM1LMAPTAOC3 | |
| SCHEMBL19597737 | 0.78 | OGA (0.46) | HRH3OGASMN1; SMN2DNM1LMAPT | |
| SCHEMBL15349313 | 0.78 | OGA (0.43) | HRH3OGASMN1; SMN2ARRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112074522-B | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-112074522-A | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2020-12-11 | — | — | CN | disclosed |